When specialist healthcare investment company Syncona Ltd discovered the ground-breaking cell therapy research being conducted by scientists at the University of Edinburgh it sparked a collaboration that went on to fuel the launch of pioneering biotechnology spinout Resolution Therapeutics.
Biotech spinout Resolution Therapeutics has announced it has raised £63.5 million in a series B financing round led by healthcare investor Syncona Ltd.
Biopharmaceutical spinout Resolution Therapeutics has announced the first patient has been dosed and safety cleared in the Phase I/II EMERALD study of its novel therapy for end-stage liver disease.
Four University of Edinburgh-supported companies have been named in Scotland’s Top 15 Tech Startups in recent analysis by data experts Beauhurst.
Taking an engineering approach to building biological systems – engineering biology – has spectacular potential to revolutionise how we diagnose and treat disease.
The Mass Spectrometry Core is a facility equipped with state-of-the-art instrumentation for sample preparation, chromatographic separation and mass spectrometry analysis for small molecule quantitation of biomarkers and drugs.
Here in Scotland, we currently have a confluence of factors – data capacity, clinical and academic expertise, and technology – that put us in pole position to translate our excellent liver disease research and to develop the innovative new treatments we need, writes Dr Prakash Ramachandran, MRC Senior Clinical Fellow and Consultant Hepatologist at the University of Edinburgh...
